Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
This study attempted to identify factors associated with mortality among human immunodeficiency virus (HIV)-infected adults starting a protease inhibitor (PI)-containing therapy. Among 1155 patients consecutively enrolled in the APROCO study between May 1997 and June 1998, clinical characteristics were as follows: median age, 36 years; median baseline CD4 cell count, 288 cells/mm(3); and median baseline plasma HIV RNA load, 4.4 log(10) copies/mL. After a median follow-up of 27 months, 48 deaths had occurred, of which 44% were related to acquired immune deficiency syndrome. The mortality rate was 2.9% at 12 months. When both data at baseline and data at 4 months after the start of PI therapy were considered, factors independently associated with mortality were (Cox model) low baseline plasma creatinine level, low school education level, low CD4 cell count at 4 months, low hemoglobin level, and elevated hepatic transaminase levels. Thus, social context plus clinical and biologic data, including the 4-month response to treatment, must be considered in treatment of HIV-infected patients.
Lewden
Charlotte
C
INSERM U330, Bordeaux, France.
Raffi
François
F
Cuzin
Lise
L
Cailleton
Valérie
V
Vildé
Jean-Louis
JL
Chêne
Geneviève
G
Allavena
Clotilde
C
Salamon
Roger
R
Leport
Catherine
C
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D004522:Educational Status; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D000637:Transaminases / Q000097:blood / Q000378:metabolism*
D017320:HIV Protease Inhibitors; D006454:Hemoglobins; D003404:Creatinine; D000637:Transaminases